Undercapitalization and overgenerous boardroom compensation for management have been major contributors to the poor performance of UK biotech.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
UK Trade and Investment. Bioscience UK (UKTI, London, 2007). <https://www.uktradeinvest.gov.uk/ukti/fileDownload/UK_Bio_Science_reflow_2_AW.pdf?cid=406181>
Ernst & Young. Beyond borders: a global perspective. Biotechnology industry report 2006. (Ernst and Young, New York, 2006).
Hemming, R. Has British biotech bottomed? Investors Chronicle (London), January 24, 2008. <http://www.investorschronicle.co.uk/Companies/ByEvent/Risk/Analysis/article/20080124/59fed530-c9b3-11dc-8b38-00144f2af8e8/Has-British-biotech-bottomed.jsp>
Davoudi, S. Biotech sees market value slip away. Financial Times (London), January 17, 2008. <http://www.ft.com/cms/s/0/28a9396e-c466-11dc-a474-0000779fd2ac.html>
Davoudi, S. Financial Times (London), 2008. <http://www.ft.com/cms/s/0/51ffe382-bf1e-11dc-8c61–0000779fd2ac.html>
Riquelmo, H. & Watson, J. Int. Small Bus. J. 20, 395–420 (2002).
Walters, L. Biotech investment trusts looking good despite challenges. Trustnet News and Research, Jan. 27, 2009. <http://www.trustnet.com/News/Research.aspx?id=34596&researchCode=Fund%20selection>
Bains, W. Drug Disc. WORLD 2004, 9–18 (2004).
Bains, W. J. Commercial Biotechnol. 12, 274–283 (2006).
Critical, I. Ltd. The equity gap: European and US biotechnology 2001–2 (Bioindustry Association, London, 2004).
Mitchell, P. Nat. Biotechnol. 23, 1029 (2005).
Critical, I. Ltd. Comparative statistics for the UK, European and US biotechnololgy sectors: analysis year 2003 (Department of Trade and Industry, London; 2005). <http://www.berr.gov.uk/files/file28439.pdf>
Klausner, A. Bio/Technology 5, 1129 (1987).
McGully, M.G. in GTCbio/s Metabolic Diseases World Summit: Partnering and Deal-making Summit (Burlingame, San Francisco, CA, USA, (2005).
Edelson, S. Biocentury 14, 1, A1–A6 (2006).
Thiel, K.A. Nat. Biotechnol. 22, 1087–1092 (2004).
Maynard, O. & Bains, W. J. Commer. Law Stud. 81, 1–37 (2008).
Vorster, G. FTSE-100 bosses take home 100 times more than average employees. Personneltoday.com, October 29, 2007. <http://www.personneltoday.com/articles/2007/10/29/43022/ftse-100-bosses-take-home-100-times-more-than-average.html>
Bains, W. J. Commercial Biotechnol. 13, 139–149 (2007).
Lawrence, S. Nat. Biotechnol. 23, 157 (2003).
Rychlik, B. & DiPierro, M. Nat. Biotechnol. 27, 98–99 (2009).
Bawden, T. Lehman and Bear Stearns join banking bonus boom. Times (London) Dec. 15, 2006.
Chong, L. Goldman staff share $16bn in bonus bonanza. Times (Lond.) Dec. 12, 2006.
Bate, L. The Current State of Biotech in Europe. MPhil thesis. Univ. Cambridge (2007).
Akram, M.S. Investment Trends in the Cambridge Biotechnology Cluster (Institute of Biotechnology, University of Cambridge, Cambridge, 2007).
Bains, W. Venture Capital and the European Biotechnology Industry (Palgrave Macmillan, Basingstoke, UK, 2008).
Acknowledgements
This article is based on theses submitted by G.S. and M.S.A. in partial fulfillment of the Cambridge University Masters in Bioscience Enterprise programme (http://www.biot.cam.ac.uk/mbe). The authors are grateful to JM Finn and Company and the Eastern Region Biotechnology Initiative for support during the preparation of these theses. The authors emphasize that specific mention of a company in this paper is not meant to imply that the company is 'better' or 'worse' than average.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare that they personally hold shares in several of the companies mentioned in this paper. J.M. Finn provides corporate investment services and advice to several of the companies mentioned.
Rights and permissions
About this article
Cite this article
Smith, G., Akram, M., Redpath, K. et al. Wasting cash—the decline of the British biotech sector. Nat Biotechnol 27, 531–537 (2009). https://doi.org/10.1038/nbt0609-531
Issue Date:
DOI: https://doi.org/10.1038/nbt0609-531